Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-label, Dose-escalation With Expansion Study of GM103 Via Intratumoral Injection, Alone and in Combination With Pembrolizumab in Adult Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

NCT06265025 is registered in ClinicalTrials.gov with GeneMedicine Co., Ltd. as lead sponsor.

NCT NCT06265025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06265025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-label, Dose-escalation With Expansion Study of GM103 Via Intratumoral Injection, Alone and in Combination With Pembrolizumab in Adult Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Lead sponsor
GeneMedicine Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 20, 2024
Completion date
October 30, 2028
Enrollment
125 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cervical cancer, colorectal cancer, head and neck cancer, malignant melanoma, renal cell carcinoma